• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.

作者信息

Minetto Paola, Guolo Fabio, Clavio Marino, Kunkl Annalisa, Colombo Nicoletta, Carminati Enrico, Fugazza Giuseppina, Matarese Simona, Guardo Daniela, Ballerini Filippo, Di Grazia Carmen, Raiola Anna M, Cagnetta Antonia, Cea Michele, Miglino Maurizio, Lemoli Roberto M, Gobbi Marco

机构信息

Haematology Clinic, Department of Internal Medicine (DiMI), University of Genoa, Policlinico San Martino, IRCCS per l'Oncologia, Genoa, Italy.

Clinical Flow Cytometry Unit, Anatomic Pathology, Policlinico San Martino, IRCCS per l'Oncologia, Genoa, Italy.

出版信息

Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23.

DOI:10.1111/bjh.15106
PMID:29359798
Abstract
摘要

相似文献

1
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information.采用氟达拉滨、阿糖胞苷和伊达比星（FLAI）诱导治疗急性髓系白血病（AML）后进行早期微小残留病评估可提供最有用的预后信息。
Br J Haematol. 2019 Feb;184(3):457-460. doi: 10.1111/bjh.15106. Epub 2018 Jan 23.
2
Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients.氟达拉滨、阿糖胞苷和低剂量伊达比星（m-FLAI）联合治疗老年急性髓系白血病患者。
Am J Hematol. 2013 Jan;88(1):10-5. doi: 10.1002/ajh.23337. Epub 2012 Oct 17.
3
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.氟达拉滨、阿糖胞苷和伊达比星（FLAI）诱导后进行风险导向巩固的高可行性和抗白血病疗效：对 10 年内单中心年轻非 M3 AML 患者的一项关键性回顾。
Am J Hematol. 2016 Aug;91(8):755-62. doi: 10.1002/ajh.24391. Epub 2016 Jun 15.
4
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.吉妥珠单抗-奥唑米星联合氟达拉滨、阿糖胞苷、伊达比星（FLAI-GO）用于65岁以下CD33阳性急性髓系白血病患者的诱导治疗。
Leuk Res. 2008 Dec;32(12):1800-8. doi: 10.1016/j.leukres.2008.05.011. Epub 2008 Jul 14.
5
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.Flai（氟达拉滨、阿糖胞苷、伊达比星）联合低剂量吉妥珠单抗奥佐米星作为 CD33 阳性 AML 的诱导治疗：一项多中心 2 期临床试验的最终结果和长期结果。
Am J Hematol. 2018 May;93(5):655-663. doi: 10.1002/ajh.25057. Epub 2018 Mar 2.
6
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.一项关于伊达比星和阿糖胞苷联合氯法拉滨或氟达拉滨用于新诊断急性髓性白血病患者的随机2期研究。
Cancer. 2017 Nov 15;123(22):4430-4439. doi: 10.1002/cncr.30883. Epub 2017 Jul 14.
7
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients.
Acta Haematol. 2007;118(1):7-9. doi: 10.1159/000100992. Epub 2007 Mar 26.
8
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.氟达拉滨、阿糖胞苷、伊达比星和依托泊苷（FLAIE），一种用于成人急性髓性白血病的四联诱导化疗方案：单中心经验
Am J Hematol. 2009 Oct;84(10):690-2. doi: 10.1002/ajh.21516.
9
Twice daily fludarabine/Ara-C associated to idarubicin, G-CSF and ATRA is an effective salvage regimen in non-promyelocytic acute myeloid leukemia.每日两次的氟达拉滨/阿糖胞苷联合伊达比星、粒细胞集落刺激因子和全反式维甲酸是治疗非早幼粒细胞性急性髓系白血病的一种有效挽救方案。
Leuk Res. 2009 Aug;33(8):1072-8. doi: 10.1016/j.leukres.2008.12.014. Epub 2009 Feb 1.
10
Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine).FLAG-Idarubicin 诱导缓解治疗与 3+7 方案（蒽环类+阿糖胞苷）相比，可改善非预后不良风险急性髓系白血病（AML）患者初次缓解后的生存。
Leuk Res. 2020 Jun;93:106318. doi: 10.1016/j.leukres.2020.106318. Epub 2020 Feb 14.

引用本文的文献

1
Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML.GIMEMA AML1718研究的安全性导入期及第一部分：维奈托克联合FLAI方案用于非低危急性髓系白血病的诱导治疗
Blood Adv. 2025 May 27;9(10):2542-2552. doi: 10.1182/bloodadvances.2024014901.
2
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy.接受强化化疗的急性髓系白血病患者中可测量残留病清除动力学的影响
Blood Adv. 2025 Feb 25;9(4):783-792. doi: 10.1182/bloodadvances.2024013826.
3
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
淋巴瘤治疗后发生的治疗相关髓系肿瘤的异基因造血细胞移植：一项代表欧洲血液与骨髓移植协会慢性恶性肿瘤工作组开展的回顾性研究
Bone Marrow Transplant. 2024 Mar;59(3):395-402. doi: 10.1038/s41409-023-02193-z. Epub 2024 Jan 9.
4
Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?社论：急性髓系白血病（AML）：是时候采用基于微小残留病（MRD）的治疗方法了吗？
Front Oncol. 2022 Sep 9;12:1020185. doi: 10.3389/fonc.2022.1020185. eCollection 2022.
5
MRD in Venetoclax-Based Treatment for AML: Does it Really Matter?基于维奈托克治疗急性髓系白血病中的微小残留病：它真的重要吗？
Front Oncol. 2022 Jul 18;12:890871. doi: 10.3389/fonc.2022.890871. eCollection 2022.
6
Measurable Residual Disease in High-Risk Acute Myeloid Leukemia.高危急性髓系白血病中的可测量残留病
Cancers (Basel). 2022 Mar 1;14(5):1278. doi: 10.3390/cancers14051278.
7
A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia.复发性或难治性急性髓系白血病患者疾病负担及临床疗效的系统文献综述
Am J Blood Res. 2021 Aug 15;11(4):325-360. eCollection 2021.
8
Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia.通过多参数流式细胞术和测序检测到的可测量残留病可改善急性髓系白血病复发和生存的预测。
Front Oncol. 2021 May 20;11:677833. doi: 10.3389/fonc.2021.677833. eCollection 2021.
9
MRD Tailored Therapy in AML: What We Have Learned So Far.急性髓系白血病中微小残留病定制疗法：我们目前所了解的情况。
Front Oncol. 2021 Jan 15;10:603636. doi: 10.3389/fonc.2020.603636. eCollection 2020.
10
Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of -ITD in Mutated AML, Irrespectively of -ITD Allelic Burden.基于氟达拉滨、大剂量阿糖胞苷和伊达比星的诱导治疗可能克服-ITD在突变型急性髓系白血病中的不良预后影响，而与-ITD等位基因负担无关。
Cancers (Basel). 2020 Dec 24;13(1):34. doi: 10.3390/cancers13010034.